Repare Therapeutics (NASDAQ:RPTX) Posts Earnings Results

Key Points

• Repare Therapeutics reported **($0.39)** earnings per share, surpassing analysts' expectations of **($0.56)** by **$0.17**, though revenue was only **$0.25 million**, falling short of the **$2.50 million** forecast.
• Analysts have upgraded Repare Therapeutics from a "sell" to a "hold" rating, with a consensus price target of **$4.50**, reflecting a cautious optimism regarding its stock performance.
• Institutional ownership accounts for **85.09%** of Repare Therapeutics, with Acadian Asset Management increasing its stake by **35.6%** in the most recent quarter.

Repare Therapeutics (NASDAQ:RPTX - Get Free Report) announced its quarterly earnings results on Friday. The company reported ($0.39) earnings per share for the quarter, beating analysts' consensus estimates of ($0.56) by $0.17, Zacks reports. The company had revenue of $0.25 million for the quarter, compared to analyst estimates of $2.50 million.

Repare Therapeutics Stock Up 1.0%

Shares of RPTX opened at $1.54 on Friday. The company has a 50-day simple moving average of $1.47 and a 200-day simple moving average of $1.30. The company has a market capitalization of $65.84 million, a PE ratio of -0.59 and a beta of 0.93. Repare Therapeutics has a 52-week low of $0.89 and a 52-week high of $4.07.

Analyst Upgrades and Downgrades

Separately, Wall Street Zen raised Repare Therapeutics from a "sell" rating to a "hold" rating in a research report on Saturday. Three analysts have rated the stock with a hold rating and two have given a buy rating to the company. According to MarketBeat, the company currently has a consensus rating of "Hold" and a consensus price target of $4.50.

Hedge Funds Weigh In On Repare Therapeutics

An institutional investor recently raised its position in Repare Therapeutics stock. Acadian Asset Management LLC grew its position in shares of Repare Therapeutics Inc. (NASDAQ:RPTX - Free Report) by 35.6% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 640,332 shares of the company's stock after purchasing an additional 168,230 shares during the period. Acadian Asset Management LLC owned 1.49% of Repare Therapeutics worth $624,000 at the end of the most recent quarter. 85.09% of the stock is currently owned by institutional investors and hedge funds.

Repare Therapeutics Company Profile

Repare Therapeutics Inc, a clinical-stage precision oncology company, engages in the discovery and development of therapeutics by using its synthetic lethality approach in Canada and the United States. It uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform, to discover, validate, and build a pipeline of SL-based therapeutics that focuses on genomic instability, including DNA damage repair.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.